← All trials
NCT04944173
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Mar 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jun 29, 2021
- Last posted
- Jun 29, 2021
- Enrollment
- 94
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of British ColumbiaLead sponsor
- AstraZenecaCollaborator
- Ozmosis Research Inc.Collaborator
- British Columbia Cancer AgencyOverall official - principal investigator
- University of British ColumbiaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.